Ole G.
- Country
- Norway
- Department
- Old age psychiatry
Research Overview
- Phase IIa Multicenter RCT on Ambroxol Efficacy in Prodromal and Mild Dementia with Lewy Bodies
- Randomized, Double-Blind, Placebo-Controlled 12-Month Study of Fasudil Hydrochloride in Patients with Early Alzheimer's Disease
- Phase 1B Dose Range Study of (-)-Phenserine Tartrate vs. Donepezil Hydrochloride in Early or Mild Alzheimer's Disease and Mild Cognitive Impairment
Data & Insights
Has run more than one trial at 7 of 7 partner sites.
Specializations
Neurodegenerative Disorders
This investigator specializes in the study of Dementia with Lewy Bodies (DLB), focusing on innovative therapeutic approaches for managing cognitive decline and neuropsychiatric symptoms.
- Cognitive Function Assessment
- Neuropsychiatric Symptom Management
- Early Disease Detection
The research encompasses evaluating therapeutic interventions in both prodromal and mild stages of DLB, with particular attention to functional outcomes.
Clinical Assessment
Expertise in conducting comprehensive evaluations of cognitive and functional outcomes in neurodegenerative conditions, with emphasis on standardized assessment tools.
- Cognitive Performance Metrics
- Functional Assessment Tools
- Disease Progression Monitoring
The investigator utilizes advanced clinical assessment methodologies to track therapeutic efficacy in neurological conditions.
Therapeutic Innovation
Focused on investigating novel therapeutic approaches for neurodegenerative disorders, particularly in early-stage intervention strategies.
- Early Intervention Protocols
- Disease-Modifying Treatments
- Therapeutic Efficacy Assessment
The research extends to evaluating innovative compounds for managing neurological conditions, with particular interest in early-stage therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.